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RESULTS: Usable response rate was 37% (n = 363). Mean A1C
was 7.2 (SD 1.4), mean diabetes duration was 10.2 (SD 9.1)
years, 62.1% were obese (BMI >30), and about 42% used
insulin. Mean (SD) and range of EQ-5D index scores were:
0.71(0.21), −0.04 to 1.00 for the US; 0.60(0.32), −0.48 to 1.00
for the UK. Spearman’s correlation between US and UK scores
was 0.998 (p < 0.001). A paired samples t-test indicated that the
US valuations were signiﬁcantly higher (p < 0.001) with the mean
difference being 0.11(0.11). In individual OLS regressions, those
with neurological complications, ischemic heart disease, obesity
or depressive symptoms had signiﬁcantly higher EQ-5D US
scores as well as UK scores. These conditions also signiﬁcantly
predicted greater differences between US and UK scores. CON-
CLUSION: Although well correlated, the U.S population means
were signiﬁcantly higher than UK population means, and this
difference was seen across clinically relevant categories in
T2DM. The preference scoring system employed may therefore
inﬂuence results of research conducted using the EQ-5D instru-
ment to measure preferences.
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OBJECTIVES: Regulatory agencies demand QALYs as evidence
of effectiveness in economic evaluation. This is a challenge for
clinical studies in which outcomes are measured using condition-
speciﬁc instruments that lack the required measurement proper-
ties. This study aims to provide a model for deriving EQ-5D
utilities directly from the QoL-AGHDA. These estimates were
used to calculate QALY deﬁcit and treatment effects in adults
with GHD in relation to the general population values.
METHODS: A UK postal survey captured QoL-AGHDA (a con-
dition-speciﬁc measure for patients with GHD) and EQ-5D
responses from a broadly representative sample of the general
population (n = 921). These data were used to construct two-
step regression model (R2 = 0.42). In the ﬁrst, TTO-weighted ED-
5Dindex was the dependent variable and yes/no responses to all 25
QoL-AGHDA items were coded as dichotomous dummy vari-
ables (xi). In the second step utilities were computed as follows:
QoL-AGHDAutility = b0 + c*age + Σbi*xi + ei. QoL-AGHDAutility
at yearly visits for 894 UK patients followed in the KIMS data-
base was computed using the same regression model. Subse-
quently the mean QALY over time were compared to baseline
values and assessed in relation to the cross-sectional age/gender
population values. RESULTS: Health related quality of life mea-
sured by QoL-AGHDAutility in patients prior to GH replacement
differed signiﬁcantly from age/gender-matched values in the
general population (0.67 vs. 0.85, p < 0.0001). After the ﬁrst
year of treatment the deﬁcit was reduced to −0.07. Despite a dra-
matic improvement during the ﬁrst year of treatment, patients’
health status remained signiﬁcantly different from general pop-
ulation reference values (p < 0.001) over the course of their treat-
ment. Nevertheless, a mean undiscounted gain from baseline of
0.32 QALYs was seen in the treated patients, corresponding to
0.08 QALYs per year. CONCLUSION: Estimates of treatment
beneﬁt for use in economic evaluation can be successfully derived
from condition-speciﬁc measures.
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OBJECTIVES: To evaluate the impact of Generalized Anxiety
Disorder (GAD) on diagnosed comorbidities, medication use and
treatment costs. METHODS: Claims were drawn from Phar-
Metrics Integrated Outcomes Database for 12-month prior and
post the ﬁrst GAD (ICD9-CM: 30002) diagnosis between
Janaury 2003 and June 2004 (the diagnosis date as the index
date). No GAD diagnosis 12-month prior the index date, 24-
month continuous insurance eligibility and aged 18–64 were
required. Changes in diagnoses of comorbidities, medication use
patterns, and treatment costs between the year before and after
the index date were examined. Comparison among subgroups of
GAD patients with comorbid depression and pain was also inves-
tigated. Wilcoxon Signed Rank test and McNemar’s test were
used to examine pre-post differences for continuous and cate-
gorical variables, respectively. RESULTS: A total of 240,041
patients were included in this study. The mean age was 41.7 years
old and 67% were female. After diagnosis of GAD, a signiﬁ-
cantly higher percent of patients were diagnosed with depression
(44.4% vs. 30.9%, p < 0.001), dyslipidemia (24.0% vs.19.9%,
p < 0.001), and diabetes (6.1% vs. 5.3%, p < 0.001) than before
GAD diagnosis. The use of antidepressants increased from
42.3% to 56.8% (p < 0.001). Compared to the year prior to
GAD diagnosis, total annual costs increased by $2034 (p <
0.001) driven mainly by increases of inpatient and outpatient
costs ($285 and $773, p < 0.001, GAD only and increased
merely $306 for GAD patients with depression while GAD
patients with pain and those with both pain and depression
increased by $2253 and $4665 (both p < 0.001), respectively.
CONCLUSION: Diagnosis of GAD had signiﬁcant impact on
comorbidities, medication use and treatment costs. Furthermore,
comorbid pain and depression had substantial extra burden on
GAD patients as compared with those had GAD only. Recog-
nizing these comorbidities is important in the treatment of
patients with GAD.
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OBJECTIVES: To compare divalproex sodium and valproic acid
for therapeutic patterns, persistence rates, and predictors of 
hospitalization among bipolar patients on monotherapy in the
Veterans Affairs Health care system. METHODS: Using VA
administrative data bases, we conducted a retrospective incep-
tion cohort study of VA patients’ °Y´ 18 years of age who had at
least one outpatient diagnoses of bipolar disorder and two con-
tinuous prescription records for the study drugs in the VA PBM
pharmacy database during the study period of April 1, 2001 to
September 30 2003. Persistence for the comparative drugs was
reported as continuous variable and compared using t-tests.
Logistic regression models were used to examine the risk of hos-
pitalization whereas Cox proportional hazard regression models
were used to evaluate the time to hospitalization and time to
interruption of therapy for the two drug groups. RESULTS: We
identiﬁed 4, 624 bipolar patients on monotherapy with valproic
acid (n = 4036) and divalproex sodium (n = 588) during the
study period. The descriptive statistics included sociodemo-
graphics, disability and comorbidity status and were similar for
the two groups. For the crude persistence rates there were no sta-
tistically signiﬁcant differences between divalproex sodium (120
days) and valproic acid (110 days). The logistic regression model
for risk of hospitalization showed no statistically signiﬁcant dif-
ference between the two comparators (OR = 1.06, 95% CI =
0.787–1.444). The Cox model for time to interruption of therapy
showed an insigniﬁcant hazard ratio for divalproex sodium
versus valproic acid (HR = 0.928, 95% CI = 0.844–1.020) and
for time to hospitalization also no statistically signiﬁcant differ-
ence in the hazard ratio for the two drugs (HR = 0.984, 95% CI
= 0.784–1.295). CONCLUSION: The study showed a compa-
rable proﬁle of generic valproic acid with divalproex sodium for
persistence and predictors of hospitalization for bipolar patients
on monotherapy in the VA. Results have important health care
implications for treatment and costs.
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OBJECTIVES: Given the high incidence of post-stroke depres-
sion (PSD), its serious sequalae, and inherent problems with
diagnosis, prophylactic use of antidepressants may be a viable
management strategy in patients experiencing stroke. The
purpose of this study was to assess the prophylactic effects 
of antidepressants in non-depressed patients with stroke.
METHODS: A meta-analysis of randomized placebo-controlled
trials (RCTs) evaluating the prophylactic effects of antidepres-
sants in non-depressed patients with stroke was conducted. Lit-
erature searches in MEDLINE, PubMed, CINAHL, PsycINFO,
EMBASE, Cochrane library, and CNKI from 1950 to August
2006 were used to identify the relevant studies. Outcome mea-
sures included the occurrence rate of newly developed PSD cases
and severity of depressive symptoms as indicated by mean
depression rating scales scores. The effect size was presented as
rate difference (RD) or weighted mean difference (WMD).
RESULTS: From 10 RCTs, a total of 703 non-depressed patients
after stroke were identiﬁed. The pooled occurrence rate of newly
developed PSD cases in the intervention and control groups were
12.54% (41/327) and 29.17% (91/312), respectively (pooled RD
= −0.17, 95% CI: −0.26 to −0.08). Prophylactic effects of anti-
depressants were not related to duration of use (coefﬁcient of
Pearson’ correlation [ã] = 0.57, p = 0.11). CONCLUSION: Anti-
depressant prophylaxis is associated with a signiﬁcant reduction
in the occurrence rate of newly developed PSD, suggesting anti-
depressants may be considered along with other vascular pre-
ventive strategies in management of stroke patients.
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OBJECTIVES: With 50–70% antipsychotic prescriptions
written for off-label purposes, the objective of this study is to
explore the pattern and the outcomes of adverse events (ADEs)
associated with antipsychotic off-label use. METHODS: A ret-
rospective pharmaco-vigilance analysis was conducted using the
FDA Adverse Event Reporting System (AERS) data between
April 2004 and March 2006. ADE cases associated with antipsy-
chotic medications were ﬁrst identiﬁed based on the role of the
medication in precipitating the ADEs (primary and secondary
suspects) and then categorized according to their intended indi-
cations as off-label/on-label uses. Thereafter, the most frequently
reported off-label antipsychotic uses associated with ADEs were
explored, and their clinical outcomes were examined and com-
pared with on-label antipsychotic ADE cases. RESULTS: Out of
27,700 ADEs involving antipsychotic medications, antipsy-
chotics were the primary suspect in 7519 cases and secondary
suspect in 2409 cases (Total: 9928). Atypical antipsychotics
accounted for majority of the cases (9122, 91.8%) with clozap-
ine (2983, 30.1%) being the most frequently reported antipsy-
chotic medication followed by quetiapine (2186, 22.0%) and
risperidone (2153, 21.7%). Off-label use afﬂicted half of the
reported ADEs cases (4767, 48%). The top three reported off-
label indications associated with ADEs include psychotic and
schizoaffective disorders (1372, 28.8%), mood disorders (1105,
23.2%) and cognitive disorders (406, 8.5%). These ADEs could
result into severe clinical outcomes. Of total 4767 ADEs associ-
ated with off-label use, (1942, 40.7%) involved hospitalizations
and (1043, 21.9% ) deaths. Similar pattern of clinical outcomes
were found in ADE cases associated with on-label antipsychotic
use. CONCLUSION: Most of the off-label antipsychotic-related
ADEs reported to FDA is associated with using atypical antipsy-
chotic medications for treating schizoaffective disorder, bipolar
disorder, depression and dementia. More than half of these ADEs
resulted in severe clinical outcomes such as hospitalizations and
death. Therefore, the risk beneﬁt ratio should be seriously con-
sidered when physicians prescribe antipsychotics for off-label
purposes.
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OBJECTIVES: To compare the risk of treatment-emergent dia-
betes (TED) in schizophrenic patients treated with atypical
(AAP) versus typical antipsychotic (TAP) medications.
METHODS: We conducted a retrospective database analysis on
episodes of care initiated after 1/1/2000 using data from Medi-
Cal. Our analysis included episodes for patients 18 years of age
or older, diagnosed with schizophrenia, who switched medica-
tions after a minimum “wash out” period of 15 days and had
no evidence of diabetes in the previous 6 months. We used a
simultaneous bivariate probit model to estimate the risk of TED
in patients treated with AAP in comparison to TAP. If the error
